drug · small molecule
lenacapavir sodium LA
Marketedupdated 3mo agoby $GILD GILEAD SCIENCES, INC.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for hiv-1 infection and 1 investigational indication.
targets
Structural capsid protein
all catalysts(10)
approval · 10
Dec 22, 2022
approval
$GILD143.44-2.82%
SUNLENCA (LENACAPAVIR SODIUM) — FDA approval
lenacapavir sodium LA
→
Dec 22, 2022
approval
$GILD143.44-2.82%
SUNLENCA (LENACAPAVIR SODIUM) — FDA approval
lenacapavir sodium LA
→
Jul 17, 2024
approval
$GILD143.44-2.82%
SUNLENCA (LENACAPAVIR SODIUM) — FDA approval
lenacapavir sodium LA
→
Jul 17, 2024
approval
$GILD143.44-2.82%
SUNLENCA (LENACAPAVIR SODIUM) — FDA approval
lenacapavir sodium LA
→
Nov 13, 2024
approval
$GILD143.44-2.82%
SUNLENCA (LENACAPAVIR SODIUM) — FDA approval
lenacapavir sodium LA
→
Nov 13, 2024
approval
$GILD143.44-2.82%
SUNLENCA (LENACAPAVIR SODIUM) — FDA approval
lenacapavir sodium LA
→
Nov 25, 2024
approval
$GILD143.44-2.82%
SUNLENCA (LENACAPAVIR SODIUM) — FDA approval
lenacapavir sodium LA
→
Nov 25, 2024
approval
$GILD143.44-2.82%
SUNLENCA (LENACAPAVIR SODIUM) — FDA approval
lenacapavir sodium LA
→
Mar 12, 2026
approval
$GILD143.44-2.82%
SUNLENCA (LENACAPAVIR SODIUM) — FDA approval
lenacapavir sodium LA
→
Mar 12, 2026
approval
$GILD143.44-2.82%
SUNLENCA (LENACAPAVIR SODIUM) — FDA approval
lenacapavir sodium LA
→
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 22, 2027
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (17)
- Aug 28, 2041method-of-use (U-3507)US 11944611
- Aug 28, 2041method-of-use (U-3507)US 11944611
- Nov 25, 2040method-of-use (U-4190)US 11807625
- Aug 16, 2038compositionUS 11267799
- Aug 16, 2038compositionUS 11267799
- Aug 16, 2038compositionUS 11267799
- Aug 16, 2038compositionUS 11267799
- Aug 17, 2037compositionUS 10071985
- Aug 17, 2037compositionUS 10071985
- Aug 17, 2037compositionUS 10071985
- Aug 17, 2037compositionUS 10071985
- Aug 17, 2037method-of-use (U-3507)US 10654827
- Aug 17, 2037method-of-use (U-3507)US 10654827
- Feb 28, 2034compositionUS 9951043
- Feb 28, 2034compositionUS 9951043
- Feb 28, 2034compositionUS 9951043
- Feb 28, 2034compositionUS 9951043
FDA exclusivities (6)
- Jun 18, 2028NPNP1.8y
- Jun 18, 2028NPNP1.8y
- Dec 22, 2027NCENew Chemical Entity (5y)1.3y
- Dec 22, 2027NCENew Chemical Entity (5y)1.3y
- Dec 22, 2027NCENew Chemical Entity (5y)1.3y
- Dec 22, 2027NCENew Chemical Entity (5y)1.3y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that